CellVoyant and Axol Bioscience announce strategic collaboration to advance AI-guided predictive imaging assays for cardiomyocyte manufacturing

Collaboration combines CellVoyant AI-powered FateView™ platform with Axol Bioscience induced pluripotent stem cell (iPSC) expertise to enable predictive, non-destructive assessment of cardiomyocyte differentiation processes, enabling the generation of highly pure cell populations at scale.

BRISTOL, UK and EDINBURGH, UK — CellVoyant, a pioneer in AI foundation models for live, label-free cell analytics and predictive cell biology, and Axol Bioscience, a leading provider of human induced pluripotent stem cell (iPSC)-derived cell models and specialist services, today announced a strategic collaboration to develop predictive AI assays for active monitoring and optimisation of cardiomyocyte manufacturing processes.

The project will integrate CellVoyant FateView™ AI-powered predictive cell analytics platform with Axol Bioscience expertise in iPSC differentiation and heart chamber-specific cardiomyocyte production. Together, the companies aim to establish non-invasive, label-free methods for predicting and guiding differentiation processes.

The collaboration focuses on applying AI-derived morphological analysis to routine transmitted- light imaging data collected during iPSC differentiation. By extracting morphologically based signatures from live-cell images, the collaboration will enable actionable in-process decision-making during differentiation to generate highly pure populations of specific cell types, initially focusing on cardiomyocyte generation for use in disease models and safety studies.

“Stem cell manufacturing continues to be constrained by biological variability and reliance on retrospective endpoint assays,” said Rafael E. Carazo Salas, Founder and CEO of CellVoyant. “Our FateView™ platform can extract predictive morphological signatures from standard transmitted-light imaging data, enabling quantitative and non-destructive assessment of cell state before differentiation outcomes are known. These insights provide a transformative opportunity to finely tune differentiation processes to drive purity of cell population and ultimately scale.”

“At Axol Bioscience, we are committed to advancing iPSC technologies that accelerate translational research and preclinical drug discovery,” said Liam Taylor, CEO of Axol Bioscience. “Collaborating with CellVoyant allows us to explore the potential of advanced AI and machine learning approaches in iPSC differentiation workflows to support production of highly pure populations of cells at scale, essential for delivering the promise of more predictive human cell models. Our special interest in developing pure heart chamber-specific cardiomyocytes is an ideal use case for Cellvoyant’s innovative approach. “

Specifically, the collaboration plans to deliver:

• AI-derived predictive metrics for assessing pluripotent stem cell readiness prior to differentiation induction
• Non-destructive go/no-go criteria for improving consistency in cardiomyocyte manufacturing workflows
• Early prediction of differentiation efficiency and purity using label-free imaging data
• Comparative assessment of cell line competence and manufacturing performance across workflows

By integrating predictive AI directly into stem cell manufacturing workflows, the partnership aims to provide earlier insight into cell-state dynamics, enabling more efficient process optimization while reducing reliance on destructive endpoint assays.

About CellVoyant

CellVoyant has pioneered cell predictive AI foundation models enabling non-destructive, real-time cell analysis and optimisation.

About Axol Bioscience

Axol Bioscience is a leading provider of human iPSC technologies, specializing in the manufacture of high-performance iPSC-derived cells and the delivery of industry-leading laboratory services.